Ativo Capital Management’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

Ativo Capital Management’s Portfolio RETA Stock Details RETA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-50,012	Closed	-$1.13M	–	242
2017 Q1	$1.13M	Hold	50,012	–	–	0.28%	134
2016 Q4	$1.09M	Sell	50,012 -4,004	-7%	-$101K	0.26%	148
2016 Q3	$1.42M	Buy	54,016 +8,807	+19%	+$175K	0.33%	90
2016 Q2	$893K	Buy	+45,209	New	+$879K	0.22%	146

Other funds holding RETA

NHAS

Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EMFAT

Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.06B AUM 106.87% 1-Year Est. Return

PAPAIJV

Paragon Associates & Paragon Associates II Joint Venture Dallas, Texas $73.6M AUM 61.93% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Ativo Capital Management's RETA Position: Q2 2017 in Review

Ativo Capital Management sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q2 2017, closing a stake of 50,012 shares — an estimated $1.13M sold.

Ativo Capital Management first reported a position in RETA in Q2 2016 and held it in 4 quarters. The position peaked at $1.42M in Q3 2016. 57 funds tracked by Wall St. Rank hold RETA as of Q2 2017.

Ativo Capital Management reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q2 2017 after selling out during the quarter.
Ativo Capital Management sold 50,012 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q2 2017, an estimated $1.13M.
Ativo Capital Management first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q2 2016 and held it in 4 quarters.
Ativo Capital Management's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $1.42M in Q3 2016.
57 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q2 2017.

Based on Ativo Capital Management's 13F filing for Q2 2017, filed 11 Aug 2017.